MicroRNA Control of Type I Interferon Signaling in CNS Autoimmunity 4397

Le résumé fourni par la source

Abstract Description IFN-β, a type I interferon, has been used as a first-line therapy for patients with multiple sclerosis (MS) for thirty years; however, the cellular and molecular basis of its therapeutic efficacy remains largely unknown. Here, we found that IFN-β and type I IFN signaling limits central nervous system autoimmunity by inhibiting microRNA-21 (miR-21)-mediated pathogenic Th17 development. Briefly, IFN-β limits miR-21 expression within CD4+ T cells, including miR-21-mediated pathogenic Th17 development, by downregulating miR-21-inducing cytokines within myeloid cells. We found miR-21 itself promotes pathogenic Th17 differentiation by inhibiting a key transcription factor, Foxo1. Accordingly, miR-21 loss abrogates pathogenic Th17 differentiation and confers resistance to experimental autoimmune encephalomyelitis, a mouse model of MS. In patient samples, we found that compared to responders of IFN-β treatment, non-responders express elevated miR-21-inducing cytokines within myeloid cells, alongside increased miR-21 and pathogenic Th17 cytokines within CD4+ T cells. Finally, direct miR-21 inhibition reduces pathogenic Th17 differentiation in non-responder CD4+ T cells. These findings provide insights into the mechanisms underlying IFN-β therapy in MS patients, suggesting that miR-21 may be a potential biomarker to predict therapeutic response, and raises the possibility that miR-21 inhibition may be of potential therapeutic value specifically for the IFN-β non-responder cohort. Funding Sources R01AI151953, R01CA267479, R01DK138260, R21AI175890 and R21AI174047 Topic Categories Neuroimmunology (NEUR)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.